| Iron Chelation Therapy 2002 Edition Contributor(s): Hershko, Chaim (Editor) |
|
 |
ISBN: 0306467852 ISBN-13: 9780306467851 Publisher: Springer OUR PRICE: $104.49 Product Type: Hardcover - Other Formats Published: January 2003 Annotation: Within the last few years, iron research has yielded exciting new insights into the understanding of normal iron homeostasis. Such development, and the evolution of improved strategies of Iron Chelating Therapy require better understanding of the pathophysiology of iron toxicity and the mechanism of action of iron chelating drugs. The timeliness of the present volume is underlined by several significant developments in recent years. New insights have been gained into the molecular basis of aberrant iron handling in hereditary disorders and the pathophysiology of iron overload. This volume highlights the impact of long term Iron Celating Therapy using deferoxamine or the new, but controversial oral iron chelator deferiprone based on experience gained by multicenter trails, with special emphasis on survival, morbidity and drug toxicity; it reviews the development of the new and improved orally effective chelators suitable for clinical use in the near future and examines novel strategies of iron chelating treatment for the control of cell proliferation in malignant disease or malaria. |
| Additional Information |
| BISAC Categories: - Medical | Endocrinology & Metabolism |
| Dewey: 616.396 |
| LCCN: 2002022131 |
| Series: Advances in Experimental Medicine and Biology |
| Physical Information: 0.93" H x 7.3" W x 9.52" (1.62 lbs) 277 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: Within the last few years, iron research has yielded exciting new insights into the under- standing of normal iron homeostasis. However, normal iron physiology offers little protec- tion from the toxic effects of pathological iron accumulation, because nature did not equip us with effective mechanisms of iron excretion. Excess iron may be effectively removed by phlebotomy in hereditary hemochromatosis, but this method cannot be applied to chronic anemias associated with iron overload. In these diseases, iron chelating therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Iron chelating therapy has changed the quality of life and life expectancy of thalassemic patients. However, the high cost and rigorous requirements of deferoxamine therapy, and the significant toxicity of deferiprone underline the need for the continued development of new and improved orally effective iron chelators. Such development, and the evolution of improved strategies of iron chelating therapy require better understanding of the pathophysiology of iron toxicity and the mechanism of action of iron chelating drugs. The timeliness of the present volume is underlined by several significant develop- ments in recent years. New insights have been gained into the molecular basis of aberrant iron handling in hereditary disorders and the pathophysiology of iron overload (Chapters 1-5). |
